Epigenome-based cancer risk prediction

Rationale, opportunities and challenges

Martin Widschwendter, Allison Jones, Iona Evans, Daniel Reisel, Joakim Dillner, Karin Sundström, Ewout W. Steyerberg, Yvonne Vergouwe, Odette Wegwarth, Felix G. Rebitschek, Uwe Siebert, Gaby Sroczynski, Inez D. De Beaufort, Ineke Bolt, David Cibula, Michal Zikan, Line Bjørge, Nicoletta Colombo, Nadia Harbeck, Frank Dudbridge & 5 others Anne Marie Tasse, Bartha M. Knoppers, Yann Joly, Andrew E. Teschendorff, Nora Pashayan

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

The incidence of cancer is continuing to rise and risk-tailored early diagnostic and/or primary prevention strategies are urgently required. The ideal risk-predictive test should: integrate the effects of both genetic and nongenetic factors and aim to capture these effects using an approach that is both biologically stable and technically reproducible; derive a score from easily accessible biological samples that acts as a surrogate for the organ in question; and enable the effectiveness of risk-reducing measures to be monitored. Substantial evidence has accumulated suggesting that the epigenome and, in particular, DNA methylation-based tests meet all of these requirements. However, the development and implementation of DNA methylation-based risk-prediction tests poses considerable challenges. In particular, the cell type specificity of DNA methylation and the extensive cellular heterogeneity of the easily accessible surrogate cells that might contain information relevant to less accessible tissues necessitates the use of novel methods in order to account for these confounding issues. Furthermore, the engagement of the scientific community with health-care professionals, policymakers and the public is required in order to identify and address the organizational, ethical, legal, social and economic challenges associated with the routine use of epigenetic testing.

Original languageEnglish
Pages (from-to)292-309
Number of pages18
JournalNature Reviews Clinical Oncology
Volume15
Issue number5
DOIs
Publication statusPublished - May 1 2018

Fingerprint

DNA Methylation
Neoplasms
Community Health Services
Primary Prevention
Epigenomics
Economics
Incidence

ASJC Scopus subject areas

  • Oncology

Cite this

Widschwendter, M., Jones, A., Evans, I., Reisel, D., Dillner, J., Sundström, K., ... Pashayan, N. (2018). Epigenome-based cancer risk prediction: Rationale, opportunities and challenges. Nature Reviews Clinical Oncology, 15(5), 292-309. https://doi.org/10.1038/nrclinonc.2018.30

Epigenome-based cancer risk prediction : Rationale, opportunities and challenges. / Widschwendter, Martin; Jones, Allison; Evans, Iona; Reisel, Daniel; Dillner, Joakim; Sundström, Karin; Steyerberg, Ewout W.; Vergouwe, Yvonne; Wegwarth, Odette; Rebitschek, Felix G.; Siebert, Uwe; Sroczynski, Gaby; De Beaufort, Inez D.; Bolt, Ineke; Cibula, David; Zikan, Michal; Bjørge, Line; Colombo, Nicoletta; Harbeck, Nadia; Dudbridge, Frank; Tasse, Anne Marie; Knoppers, Bartha M.; Joly, Yann; Teschendorff, Andrew E.; Pashayan, Nora.

In: Nature Reviews Clinical Oncology, Vol. 15, No. 5, 01.05.2018, p. 292-309.

Research output: Contribution to journalReview article

Widschwendter, M, Jones, A, Evans, I, Reisel, D, Dillner, J, Sundström, K, Steyerberg, EW, Vergouwe, Y, Wegwarth, O, Rebitschek, FG, Siebert, U, Sroczynski, G, De Beaufort, ID, Bolt, I, Cibula, D, Zikan, M, Bjørge, L, Colombo, N, Harbeck, N, Dudbridge, F, Tasse, AM, Knoppers, BM, Joly, Y, Teschendorff, AE & Pashayan, N 2018, 'Epigenome-based cancer risk prediction: Rationale, opportunities and challenges', Nature Reviews Clinical Oncology, vol. 15, no. 5, pp. 292-309. https://doi.org/10.1038/nrclinonc.2018.30
Widschwendter M, Jones A, Evans I, Reisel D, Dillner J, Sundström K et al. Epigenome-based cancer risk prediction: Rationale, opportunities and challenges. Nature Reviews Clinical Oncology. 2018 May 1;15(5):292-309. https://doi.org/10.1038/nrclinonc.2018.30
Widschwendter, Martin ; Jones, Allison ; Evans, Iona ; Reisel, Daniel ; Dillner, Joakim ; Sundström, Karin ; Steyerberg, Ewout W. ; Vergouwe, Yvonne ; Wegwarth, Odette ; Rebitschek, Felix G. ; Siebert, Uwe ; Sroczynski, Gaby ; De Beaufort, Inez D. ; Bolt, Ineke ; Cibula, David ; Zikan, Michal ; Bjørge, Line ; Colombo, Nicoletta ; Harbeck, Nadia ; Dudbridge, Frank ; Tasse, Anne Marie ; Knoppers, Bartha M. ; Joly, Yann ; Teschendorff, Andrew E. ; Pashayan, Nora. / Epigenome-based cancer risk prediction : Rationale, opportunities and challenges. In: Nature Reviews Clinical Oncology. 2018 ; Vol. 15, No. 5. pp. 292-309.
@article{46e7bfc96e974d0cb68fc82943ed4fbf,
title = "Epigenome-based cancer risk prediction: Rationale, opportunities and challenges",
abstract = "The incidence of cancer is continuing to rise and risk-tailored early diagnostic and/or primary prevention strategies are urgently required. The ideal risk-predictive test should: integrate the effects of both genetic and nongenetic factors and aim to capture these effects using an approach that is both biologically stable and technically reproducible; derive a score from easily accessible biological samples that acts as a surrogate for the organ in question; and enable the effectiveness of risk-reducing measures to be monitored. Substantial evidence has accumulated suggesting that the epigenome and, in particular, DNA methylation-based tests meet all of these requirements. However, the development and implementation of DNA methylation-based risk-prediction tests poses considerable challenges. In particular, the cell type specificity of DNA methylation and the extensive cellular heterogeneity of the easily accessible surrogate cells that might contain information relevant to less accessible tissues necessitates the use of novel methods in order to account for these confounding issues. Furthermore, the engagement of the scientific community with health-care professionals, policymakers and the public is required in order to identify and address the organizational, ethical, legal, social and economic challenges associated with the routine use of epigenetic testing.",
author = "Martin Widschwendter and Allison Jones and Iona Evans and Daniel Reisel and Joakim Dillner and Karin Sundstr{\"o}m and Steyerberg, {Ewout W.} and Yvonne Vergouwe and Odette Wegwarth and Rebitschek, {Felix G.} and Uwe Siebert and Gaby Sroczynski and {De Beaufort}, {Inez D.} and Ineke Bolt and David Cibula and Michal Zikan and Line Bj{\o}rge and Nicoletta Colombo and Nadia Harbeck and Frank Dudbridge and Tasse, {Anne Marie} and Knoppers, {Bartha M.} and Yann Joly and Teschendorff, {Andrew E.} and Nora Pashayan",
year = "2018",
month = "5",
day = "1",
doi = "10.1038/nrclinonc.2018.30",
language = "English",
volume = "15",
pages = "292--309",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Epigenome-based cancer risk prediction

T2 - Rationale, opportunities and challenges

AU - Widschwendter, Martin

AU - Jones, Allison

AU - Evans, Iona

AU - Reisel, Daniel

AU - Dillner, Joakim

AU - Sundström, Karin

AU - Steyerberg, Ewout W.

AU - Vergouwe, Yvonne

AU - Wegwarth, Odette

AU - Rebitschek, Felix G.

AU - Siebert, Uwe

AU - Sroczynski, Gaby

AU - De Beaufort, Inez D.

AU - Bolt, Ineke

AU - Cibula, David

AU - Zikan, Michal

AU - Bjørge, Line

AU - Colombo, Nicoletta

AU - Harbeck, Nadia

AU - Dudbridge, Frank

AU - Tasse, Anne Marie

AU - Knoppers, Bartha M.

AU - Joly, Yann

AU - Teschendorff, Andrew E.

AU - Pashayan, Nora

PY - 2018/5/1

Y1 - 2018/5/1

N2 - The incidence of cancer is continuing to rise and risk-tailored early diagnostic and/or primary prevention strategies are urgently required. The ideal risk-predictive test should: integrate the effects of both genetic and nongenetic factors and aim to capture these effects using an approach that is both biologically stable and technically reproducible; derive a score from easily accessible biological samples that acts as a surrogate for the organ in question; and enable the effectiveness of risk-reducing measures to be monitored. Substantial evidence has accumulated suggesting that the epigenome and, in particular, DNA methylation-based tests meet all of these requirements. However, the development and implementation of DNA methylation-based risk-prediction tests poses considerable challenges. In particular, the cell type specificity of DNA methylation and the extensive cellular heterogeneity of the easily accessible surrogate cells that might contain information relevant to less accessible tissues necessitates the use of novel methods in order to account for these confounding issues. Furthermore, the engagement of the scientific community with health-care professionals, policymakers and the public is required in order to identify and address the organizational, ethical, legal, social and economic challenges associated with the routine use of epigenetic testing.

AB - The incidence of cancer is continuing to rise and risk-tailored early diagnostic and/or primary prevention strategies are urgently required. The ideal risk-predictive test should: integrate the effects of both genetic and nongenetic factors and aim to capture these effects using an approach that is both biologically stable and technically reproducible; derive a score from easily accessible biological samples that acts as a surrogate for the organ in question; and enable the effectiveness of risk-reducing measures to be monitored. Substantial evidence has accumulated suggesting that the epigenome and, in particular, DNA methylation-based tests meet all of these requirements. However, the development and implementation of DNA methylation-based risk-prediction tests poses considerable challenges. In particular, the cell type specificity of DNA methylation and the extensive cellular heterogeneity of the easily accessible surrogate cells that might contain information relevant to less accessible tissues necessitates the use of novel methods in order to account for these confounding issues. Furthermore, the engagement of the scientific community with health-care professionals, policymakers and the public is required in order to identify and address the organizational, ethical, legal, social and economic challenges associated with the routine use of epigenetic testing.

UR - http://www.scopus.com/inward/record.url?scp=85045578014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045578014&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2018.30

DO - 10.1038/nrclinonc.2018.30

M3 - Review article

VL - 15

SP - 292

EP - 309

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 5

ER -